Citigroup Maintains Buy on ArriVent BioPharma, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has maintained a Buy rating on ArriVent BioPharma and increased the price target from $30 to $36.
September 11, 2024 | 4:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup has reaffirmed its Buy rating on ArriVent BioPharma and increased the price target from $30 to $36, indicating a positive outlook.
The increase in price target from $30 to $36 by Citigroup suggests a positive outlook for ArriVent BioPharma, likely leading to a short-term increase in stock price as investors react to the analyst's confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100